Gedeon Richter Media Richter publishes Q2 results
Richter publishes Q2 results
06/08/2025
Tracking in line with guidance after strong Q2
  • Pharma revenues grew by 11% to HUF 458bn in H1 2025, supported by accelerating sales growth in WHC and continued strong demand growth for Vraylar. Ex-Fx revenue growth was 8%.
  • Net profit was at HUF 120bn in H1 2025, 13% lower YoY, despite higher operating profits, due to the lack of FX gains. Free cash-flow was robust and stable at HUF 111bn in H1 2025.
  • Innovation in focus in Q2: A second phase 2 clinical trial was initiated in the AbbVie-partnered program, RGH-932; the Granata Bio partnership marks an important step in establishing our presence in the US fertility market.
  • Full-year guidance of around 10% increase (ex-FX) in both revenues and Clean EBIT is maintained

 

Budapest, 6 August 2025 - Gedeon Richter Plc. (“Richter”) announced today its Q2/H1 2025 financial results.

Pharma revenues grew by 11% YoY to HUF 237.5bn in Q2 2025, bringing H1 2025 revenues to HUF 458bn (also +11% YoY). Excluding currency changes (ex-FX), revenue growth was 8%, catching up with the annual guidance (around 10% growth). 

  • CNS revenues increased by 14% in H1 2025 YoY on the back of continued strong, double-digit demand growth for Vraylar. Reagila® kept on performing well in Richter’s own network, but revenues from certain partnered territories decreased due to overstock or timing of deliveries.
  • Women’s Healthcare sales growth accelerated significantly in Q2 (+19%), bringing the H1 growth into the double-digit range, despite the significant base effect (pre-shipments in H1 2024). Bulk of the growth was delivered by Western and Eastern European markets. All the smaller focus therapeutic segments (fertility, menopause and endometriosis) saw double-digit growth in both Q2 and H1 and contraception also recorded higher sales YoY.
  • BIO revenues growth moderated somewhat in Q2, yet both teriparatide and CDMO revenues were up around 10% in H1 2015 YoY.
  • GenMed revenue growth saw a material slowdown in Q2, affected by the high base and weaker volumes, despite supportive FX and pricing. Consequently, the FX-adjusted growth was only 5% in H1 YoY.

Gross profit (pharma) grew by 11% to HUF 321bn, while gross margin was marginally higher (+0.2ppt) at 70.2% in H1 2025.

Clean EBIT (pharma) rose by 21% YoY in Q2 2025 to HUF 79bn, bringing H1 2025 Clean EBIT to HUF 147bn, up by 14.5% YoY driven by higher CNS earnings and narrowing BIO losses.

Reported EBIT stood at HUF 140bn in H1 2025, rising 11% YoY.

Net profit (attributable to the owners of the parent) was HUF 120bn in H1 2025, declining by 13% from last year, as net financials only marginally added to profits (HUF 3.2bn) vs. large financial income (HUF 24.2bn) a year ago (on large FX gains). 

Free cash flow (before M&A) was nearly unchanged YoY at HUF 111bn in H1, as higher EBIT and lower capex was offset by some realized FX losses. Cash was used only in smaller transactions, while the majority of the FCF was paid out in Q2 as the regular annual dividend (HUF 93bn, +18% YoY). 

Important progress was made in the Innovative businesses in Q2 2025. In Neuropsychiatry, the AbbVie-partnered program, RGH-932 (D2/D3 agonist) entered into Phase 2 development in Generalized Anxiety Disorder (GAD); with that there are now two ongoing Phase 2 clinical trials related to the molecule. Further progress was also made in the other AbbVie-partnered project under the 2022 R&D collaboration agreement, which is in preclinical phase. In Women’s Healthcare, collaboration was strengthened with Granata Bio, a US-based company focused on reproductive health. This is a crucial step to establish our presence in the fertility market in the United States – in line with our strategic ambitions to bring Richter assets to and advance fertility treatments in this key market.

 

Gábor Orbán, CEO commented the results:

“Women’s Healthcare shifted gears, Vraylar continued to enjoy strong demand growth, and Biotech losses narrowed in the last quarter. With a robust Q2 we are now tracking in line with our annual guidance despite the strong base. Our innovative pillar has seen important progress lately: in Neuroscience a second phase 2 clinical trial (in GAD) was initiated in the AbbVie-partnered program, RGH-932, thus two parallel phase 2 studies are running now, while preclinical projects also are moving forward according to plan. The Granata Bio partnership marks an important step in establishing our presence in the US fertility market, which, coupled with the strong momentum in menopause, endometriosis and fertility more broadly, makes us confident that we are on the right track in executing our strategy.“

 

About Gedeon Richter Plc.

Richter aspires to be a global innovator in some key scientific fields, while dedicated to making medicines more accessible worldwide. Founded in 1901, headquartered in Hungary, with a market capitalization of EUR 4.7bn and sales of EUR 2.2bn in 2024, it operates Central Europe's largest R&D hub. Its research drives breakthroughs in Neuropsychiatry and Women's Healthcare, while Biotechnology and General Medicines strengthen its affordable treatment portfolio. Committed to sustainable growth, Richter invests in R&D, manufacturing excellence, and digitalization to advance medical innovation. Learn more at www.gedeonrichter.com

 

For further information:

Investors: Róbert Réthy, CFA / +36 20 342 2555

Media: Zsuzsa Beke / +36 20 916 4507